MO-C2N-DIAGNOSTICS
C₂N Diagnostics, LLC, a leader in advanced brain health diagnostics, and Eisai Inc., a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.
C₂N executives say the investment reflects the two companies’ shared desire to scale up and provide broad access to its Precivity™ tests, which are innovative blood tests intended for use in patients with cognitive impairment. These tests aim to help healthcare providers determine Alzheimer’s disease pathology, and aid in medical management and treatment decisions.
The companies agree that Eisai’s investment will catalyze C₂N’s efforts to expand the availability, accessibility and use of high-performance blood biomarker tests for the early diagnosis of Alzheimer’s disease in the U.S.
Dr. Joel Braunstein, C₂N’s CEO, said, “We greatly appreciate the dedication and thoroughness Eisai brought to evaluating the value and quality of our advanced diagnostic solutions in the field of brain health. With this financing, we’re building on our history of attracting the highest-quality investors committed to changing the trajectory of Alzheimer’s disease through early detection and treatment and, ultimately, prevention. We’re proud to have Eisai’s leadership in the field as we’re transforming the management and clinical care standard for patients with Alzheimer’s disease. The availability of blood biomarkers that are closely correlated with gold standard measures, such as positron emission tomography (PET) scans, will improve accessibility for patients to obtain safe and effective drug treatments as more become available.”
“The field of highly accurate blood-based diagnostics is rapidly advancing and expanding,” said Keisuke Naito, Global Alzheimer's Disease Officer, Senior Vice President, Eisai. “Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth. The availability of more affordable and minimally invasive diagnostic tools helps support broad access for the management of Alzheimer’s disease.”
C2N and Eisai initially announced in 2022 that they were working “to build awareness and develop real-world evidence to support the use of blood-based assays in people living with cognitive impairment who are not currently participating in a clinical trial.”
About C2N Diagnostics, LLC
C₂N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C₂N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C₂N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C₂N assays have been used in over 150 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. C₂N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums. Over 15,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.
The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation and Alzheimer’s Association. For more information visit www.C2N.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306427979/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Murata Automotive-Compliant Chip Ferrite Beads Deliver Wide Band Noise Suppression of High-Frequency (5.9GHz) C-V2X19.6.2025 04:00:00 CEST | Press release
The new BLM15VM series is ideal for automotive powertrains and safety applications. It supports high frequencies. 1000Ω (Typ.) @5.9GHz. With its compact 0402-inch size (1.0×0.5mm) can operate at temperatures ranging from -55 to 150°C. And it is compliant with AEC-Q200. Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) continues to push the envelope in automotive noise suppression technology with another industry first. By leveraging proprietary material technology and optimized structural design, the company’s new BLM15VM series of automotive-compliant chip ferrite beads deliver wide-band noise suppression of high-frequency (5.9GHz) 5G vehicle-to-everything (5G-V2X) applications that exhibit high impedance. Mass production is scheduled to begin in July 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618511573/en/ [Murata Manufacturing Co., Ltd.] New Chip Ferrite Beads for Automotive In recent years, t
AV and UAS Denmark Establish Strategic Partnership to Advance Allied UAS Capabilities in Europe18.6.2025 22:30:00 CEST | Press release
AeroVironment, Inc. (“AV”) (NASDAQ: AVAV) today announced it has signed a Memorandum of Understanding (MOU) with Hans Christian Andersen Aiport in Odense, Denmark–home to the UAS Denmark Test Center–to explore joint utilization of the center’s expansive airspace and advanced test facilities. The agreement aims to leverage UAS Denmark’s strategic range and infrastructure to support AV’s uncrewed aircraft system (UAS) demonstration operations, mission training, and customer integration activities across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618380337/en/ JUMP 20 executes a seamless landing on a moving ship (Photo: AV) The collaboration is expected to enable joint research and development (R&D) initiatives and accelerate the growth of the UAS Denmark Test Center as a regional epicenter for advanced UAS innovation, evaluation, and operational readiness. "This MOU represents a significant milestone in expa
Stone Harbor Investment Partners Introduces Emerging Markets Climate Impact Debt Fund18.6.2025 22:05:00 CEST | Press release
Actively managed, sustainable UCITS fund targets emerging market countriesThis is a marketing communication. Stone Harbor Investment Partners, an investment manager of Virtus Investment Partners, Inc. (NYSE: VRTS), has launched the Stone Harbor Emerging Markets Climate Impact Debt (Bloomberg: STHEMDI) (the “Fund”), a UCITS fund classified as Article 9 under the Sustainable Finance Disclosure Regulation (SFDR) that addresses decarbonization efforts occurring in Emerging Markets (EM) while seeking to deliver attractive long-term total returns for investors. The Fund invests in sustainable debt issued with proceeds dedicated to environmental activities, assets, projects or expenditures, with social bonds also permissible, of EM corporate, sovereign, quasi-sovereign and supranational issuers in hard currency. The Fund, with a sustainable objective to promote the transition towards an environmentally and socially sustainable economy, seeks to outperform the J.P Morgan EM Credit Green, Socia
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma18.6.2025 21:39:00 CEST | Press release
- Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) - Patients with relapsed or refractory FL achieved significantly improved progression-free survival with Monjuvi in combination with rituximab and lenalidomide in the Phase 3 registration trial - This milestone represents the second approved indication for Monjuvi in the United States Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615896694/en/ MONJUVI logo "Patients living with relapsed or refr
Andersen Consulting fortsætter sin globale udvidelse med tilføjelsen af Azurian Consulting18.6.2025 19:49:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine evner inden for virksomhedstransformation, teknologi og kunstig intelligens via en samarbejdsaftale med Azurian Consulting. Azurian Consulting, der blev grundlagt i 2012, tilbyder en omfattende række af tjenester, herunder transformation af digital strategi, databaseret strategi, optimering af forretningsprocesser og forandringsledelse. Med base i Latinamerika hjælper Azurian Consulting kunder inden for en bred vifte af brancher såsom finansverdenen, detailhandel, forbrugervarer og fremstillingsindustrien. "Samarbejdet med Andersen Consulting åbner døren til nye markeder, styrker vores evne til at hjælpe multinationale kunder og giver vores team adgang til globale ressourcer," udtaler Nicolás Dueñas, der er administrerende direktør for Azurian Consulting. "Det repræsenterer en stærk synergi, der giver os mulighed for at kombinere vores regionale indsigt med Andersen Consultings globale platform og dermed styrke vores evne til at levere integrerede og sa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom